Abstract
Introduction IL-4 receptor (IL-4R)-mediated alternative activation of macrophage drives type 2 airway inflammation. Cadherin-26 (CDH26) upregulates epithelial type II IL-4R signaling in asthma. However, whether CDH26 contributes to type I IL-4R-mediated macrophage activation and the mechanism by which CDH26 upregulates IL-4R expression remains unknown.
Methods CDH26 expression in bronchoalveolar lavage cells of asthma patients was examined using quantitative PCR and immunostaining. Airway inflammation and macrophage activation were assessed in ovalbumin-sensitized and challenged Cdh26fl/flLyz2Cre and control mice. Mechanistic experiments included IL-4Rα degradation and ubiquitination assay, CDH26 co-immunoprecipitation and mass spectrometry analysis. Cdh26 siRNA encapsulated lipid nanoparticles were used to treat the mouse model.
Results CDH26 expression was enhanced in bronchoalveolar lavage cells from patients with eosinophilic asthma and was localized to macrophages. Airway eosinophilia, mucous cell metaplasia and macrophage alternative activation were significantly suppressed in ovalbumin-challenged Cdh26fl/flLyz2Cre mice compared to control mice. Cdh26 deficiency inhibited the expression of M2 markers as well as IL-4Rα expression in mouse bronchoalveolar lavage macrophages, cultured bone marrow-derived macrophages, and primary lung macrophages. Furthermore, CDH26 knockdown enhanced whereas CDH26 overexpression suppressed IL-4Rα ubiquitination and proteasomal degradation in vitro. Mechanistically, CDH26 directly interacts with STUB1 and suppresses the binding of STUB1 to IL-4Rα and subsequent ubiquitination-proteasomal degradation. Cdh26 siRNA encapsulated lipid nanoparticles markedly alleviated airway eosinophilia, mucus metaplasia and macrophage alternative activation in the mouse model.
Conclusions CDH26 interacts with STUB1 and suppresses STUB1-mediated IL-4Rα ubiquitination-proteasomal degradation, thereby amplifying IL-4R signaling in macrophages in asthma. CDH26 is a potential therapeutic target for asthma.
Take-Home Message Macrophage CDH26 is upregulated in asthma patients, and Cdh26 deficiency suppresses macrophage alternative activation. CDH26 directly interacts with STUB1 and inhibits STUB1-mediated IL-4Rα ubiquitination and degradation, thus amplifying IL-4R signaling.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is supported by National Natural Science Foundation of China (grant 82170036), Key Research and Development Program of Hubei Province (grant 2024BCB280), Innovation and Translation Project of Tongji Hospital (grant 2023CXZH006), Natural Science Foundation of Hubei Province (2024AFB622), Research Foundation of Tongji Hospital (2023B06)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the ethics committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.